NHS Breast Screening

Irene Campbell Excerpts

Monday 29th June 2026 Westminster Hall

[Irene Campbell (North Ayrshire and Arran) (Lab)]

I beg to move,

That this House has considered e-petition 742179 relating to NHS breast screening.

It is a pleasure to serve under your chairmanship, Mr Vickers. I would like to start by thanking the petitioner, Gemma Reeves, for all the hard work she has put into starting the petition and gathering over 106,000 signatures from across the UK. The petition is titled “Lower the age for invites to regular mammograms to 40 & perform annually”, and says:

“Lower the age for when you are first called to 40 and provide funding to carry out Mammograms Annually instead of every Three Years.

Early detection is key and the prevalence of Breast Cancer in young patients is rising.

I am a Chemotherapy Nurse and working in this Clinical Setting for 8 Years and I have seen a rise in Breast Cancer in Patients under the Age of 40 increase.

Early detection is key in identifying those Aggressive forms of Breast Cancer”.

This is an issue that many people here and outside the Chamber care deeply about. Breast cancer still affects too many women, and far too many women die from it every year. I had the privilege of meeting with Gemma, who is here today. She told me about her experience of being a nurse for 15 years, eight of which have been in oncology, and about her concerns from having seen a rise in breast cancer cases in younger women, especially since covid.

Breast cancer is the most common type of cancer for women in the UK—one in seven women may get it. As Gemma wrote in her petition, “Early detection is key”, and has led to improved recovery and survival rates. Over half of breast cancer cases occur in women outside the national screening age, and one in six occur in women under 50. Men, too, get breast cancer; however, they make up approximately 1% of all cases. Currently, the NHS invites women to come to their first breast screening between the ages of 50 and 53, and this goes on until they are 71. They are invited every three years, after which a woman can choose to continue going for mammograms, but will not be automatically invited. Although everyone is at risk of breast cancer, women are at a higher risk if they are over 50, have dense breast tissue, have a family history of breast or ovarian cancer, or have particular breast conditions, for example benign breast disease.

There is a breast screening pathway for those identified as NHS-targeted very high risk. It is also important to note that NICE guidelines recommend annual mammography scans for women aged between 40 and 49 at moderate risk, as well as annual mammography or MRI surveillance for some high-risk groups.

[Jim Shannon (Strangford) (DUP)]

I commend the hon. Lady for securing this debate. Unfortunately, many women are diagnosed with this cancer each year. Invasive lobular breast cancer accounts for some 15% of all breast cancer cases, yet it is routinely missed until it reaches an advanced stage. Hundreds of members of this House have backed the call for a dedicated £20 million five-year research investment into the fundamental biology of lobular cancers. Does the hon. Lady agree that the Minister—I believe she is sympathetic to this—must undertake to incorporate advanced screening technologies, such as contrast-enhanced mammography or MRI, into the NHS pathway for women with dense breast tissue or a suspected lobular profile? The Government must grasp the issue and do something now.

[Irene Campbell]

I thank the hon. Member for his intervention. I, too, look forward to hearing the Minister’s response on that issue.

Some 1.94 million women between the ages of 50 and 70 were screened in 2024-25, and almost 20,000 cancers were detected. Cancers were detected in nine in every 1,000 women, which is a 16% increase on the previous year. Attendance to screening reached the highest level in a decade and has been championed by charities such as Breast Cancer Now, which shares public figures, stories and personal messages.

[Peter Fortune (Bromley and Biggin Hill) (Con)]

I thank the hon. Member for securing this important debate. Does she share my concern about the difference between the numbers of first-time attendees to screening and returning attendees, at 89.1% and 63% respectively? Does she have a view on how we can increase the number attending their first screening?

[Irene Campbell]

Screening is key, and we have to be bolder and more inventive about how we get people along to screening. There have been many public health campaigns over the years. After a campaign, there is always a rise in attendance, but when the campaign stops, attendance falls again, so I agree that that is something that the Minister must look at.

[Patricia Ferguson (Glasgow West) (Lab)]

The hon. Member for Bromley and Biggin Hill (Peter Fortune) makes a valid point. Is my hon. Friend aware that between 2020 and 2023, more than three in four women in Scotland took up their screening invitations? However, take-up is varied based on deprivation: 64.2% of women in the most deprived areas attended, compared with 82.8% in the least deprived areas. Breast cancer survival rates reflect that; women from more deprived areas in particular are more likely to die at an earlier age, because they have not been for screening and are diagnosed late. Making screening available to people in innovative ways is important, but so too is screening people in their neighbourhoods. Does my hon. Friend agree?

[Irene Campbell]

I fully agree with my hon. Friend. Unfortunately, that is not just the case for breast screening; bowel cancer screening is lower in areas of economic and health deprivation. We must look at how we target those populations.

It is key that we continue to increase awareness of the importance of routine health appointments and modifiable risk factors. Although screening is increasing generally, the NHS breast screening programme found that one in three women still do not take up their offer of screening. As my hon. Friend said, it is key that we continue with strategies that promote the uptake of screening in areas of lower attendance such as by running awareness campaigns, sending reminder texts and deploying mobile screening units, among other strategies. In preparing for this debate, I met Breast Cancer Now, as well as CoppaFeel!, the UK’s only youth-focused breast cancer awareness charity. They call for more screening of women who have a higher risk of breast cancer, as well as providing women identified with wraparound support.

Diagnostics are key to identifying those with breast cancer successfully, although mammography is not always the best diagnostic tool, particularly for younger women and those with dense breast tissue, so it is important to invest in other diagnostics, such as MRIs, and to consider their capacity to be scaled and expanded. Younger women tend also to have denser breasts, which mammograms are worse at analysing as the scans are harder to interpret. That can lead to women having repeated scans and extended investigations.

It is important to note that most European countries screen for breast cancer between the ages of 50 and 69, although there is some variation in age ranges and frequency, with countries such as Albania, Iceland and Sweden starting screening at 40. Although breast cancer diagnoses for women under 40 are rarer, and about 4% of breast cancer cases in the UK are in women under 40, when young women get breast cancer, they are much more likely than older women to have a family history of breast cancer and genetic mutations that are associated with increased risk.

There is an ongoing trial called AgeX, which is looking at the benefits of regularly screening women aged 47 to 49 and aged 71 to 73, given how little is known about screening women outside the ages of 50 to 70. The trial took place from 2009 until 2020, and 4 million women took part. The first report to come out of the trials is due in December 2026 and the final report is due in 2031, so it will be a few years before we know its findings. Other trials include the UK age trial, led by Professor Stephen Duffy, which looked into the effectiveness of annual mammographic screening for women in their 40s and found that the mortality benefit was greatest for the first decade after screening started.

[Mr Will Forster (Woking) (LD)]

I am proud to have Walk The Walk—one of the country’s leading breast cancer charities, which has raised a huge amount of money and awareness—in my constituency. It is pushing for mammogram testing to be extended. Does the hon. Lady agree that extending it to the under-40s and the over-70s could have a notable effect on fighting this deadly cancer?

[Irene Campbell]

I agree, and I look forward to hearing the Minister talk about how we can take this forward.

The UK National Screening Committee is still concerned about false positives, overdiagnosis and over-treatment. In 2012, Sir Michael Marmot chaired an independent review of breast screening, which found that the current UK screening programme prevents about 1,300 deaths from breast cancer annually. However, he also found that overdiagnosis meant that, for every death prevented by screening, about three women are treated for a cancer that they do not have. As breast cancer is less common in younger women, there is a concern that overdiagnosis would be much higher in that age group. False positive results can induce long-lasting anxiety and an unwillingness to attend future screenings. It is important that screening programmes accurately weigh up the balance between potential harms and benefits. I am sure we will hear more about that in the debate.

It is a common misconception that breast cancer is not a problem any more, but more women die from breast cancers than from other cancers. We need to do more to look after women in their 40s and women under 40. We need risk-adapted screening to better improve our chances of early detection in the most vulnerable. I look forward to hearing from other Members and the Minister.

[Several hon. Members rose—]

--- Later in debate ---

[Irene Campbell]

It has been a privilege to open and close such an important debate. We have heard from many Members and the Minister about how important early diagnosis and treatment are for breast cancer, and how key it is that we tackle this issue quickly and effectively. We have also heard about health inequalities and deprivation, and how they can impact the take-up of screening opportunities. We must do more to address that.

The NHS 10-year plan has committed to diagnosing 75% of cancers early by 2028, and the national cancer plan has a 75% five-year survival target for all cancers. This is an area that is very important to so many people across the UK, and we must do all we can as a Government to improve recovery and survival from cancer, particularly the most common type of cancer in women.

I would like to finish by thanking the petitioner, Gemma Reeves, again and congratulating her on gathering over 106,000 signatures, which is a great achievement.

I would also like to thank Lily Parsey, Sophie Conway and Lily Ewin from CoppaFeel!, Nele Gewert and Hannah Maybour from Breast Cancer Now, Cristina Visintin and Ros Given-Wilson from the UK National Screening Committee, and Professor Sacha Howell and Sarah Hindmarch from Manchester University for meeting me and my team before this debate.

Finally, as always, I thank the staff of the Petitions Committee, who work tirelessly every week to make sure that these debates go ahead in such a smooth and effective way.

Question put and agreed to.

Resolved,

That this House has considered e-petition 742179 relating to NHS breast screening.